Thermo Fisher Scientific Inotuzumab Humanized Recombinant Human Monoclonal Antibody

Thermo Fisher Scientific Inotuzumab Humanized Recombinant Human Monoclonal Antibody

Applications

• ELISA (assay-dependent)

Product Specifications

Product Specific Information

• Endotoxin level < 0.01 EU/µg by LAL method
• Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
• Store at 2–8°C for up to one week.
• Store at -20 to -80°C for up to twelve months from the date of receipt.

Target Information

Inotuzumab ozogamicin is an antibody-pharmaceutical conjugate using linker and cytotoxic pharmaceutical technology similar to that developed for Mylotarg (Gemtuzumab ozogamicin), approved by the US FDA in 2000 for acute myeloid leukemia.
It consists of a recombinant humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to the calicheamicin derivative N-acetyl-gamma-calicheamicin dimethylhydrazide, a potent DNA-binding cytotoxic agent.
Developed by Pfizer and UCB, inotuzumab ozogamicin was approved by the EU in June 2017 and by the FDA on August 17, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
In a randomized trial, inotuzumab ozogamicin showed higher complete remission rates compared to alternative chemotherapies.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.